2011 ADA Posters 1261-2041.indd - Diabetes
2011 ADA Posters 1261-2041.indd - Diabetes
2011 ADA Posters 1261-2041.indd - Diabetes
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Integrated Physiology/<br />
Obesity<br />
POSTERS<br />
novel long-term model indicates that diabetes contributes to progression<br />
from NASH to more end-stage liver disease. Subsequent studies will further<br />
defi ne molecular mechanisms of this process. Supported by NHMRC of<br />
Australia Project Grant #632822.<br />
Supported by: NHMRC of Australia Project Grant No. 632822<br />
1683-P<br />
Differential Response of Mitochondrial Enzymes to Obesity and<br />
Excessive Dietary Fat Intake<br />
ELIZAVETA V. MENCHIKOVA, WAN HUANG, FREDERICO G.S. TOLEDO, ROBERT<br />
M. O’DOHERTY, BRET H. GOODPASTER, VLADIMIR B. RITOV, Pittsburgh, PA<br />
The current study was undertaken to compare the effect of obesity or<br />
excessive fat intake on specifi c activity (per mitochondria mass) of electrontransport<br />
chain (NADH-oxidase) and TCA cycle (citrate synthase (CS) that<br />
provides entrance of acetyls into TCA cycle) enzymes in human skeletal muscle<br />
and rat liver. Tissue cardiolipin (CL) content was measured as independent<br />
non-enzymatic marker of mitochondrial mass. We compared CL, NADHoxidase<br />
and CS activity in skeletal muscle biopsies from sedentary lean<br />
insulin sensitive (L, n=9, age 47±2, BMI 24±1) and sedentary obese insulin<br />
resistant (Ob, n=15, age 42±3, BMI 35±1) subjects. There is no difference<br />
in CL content in skeletal muscle from L and Ob (74±9 and 76±6 μg/mU CK,<br />
respectively). The activity of NADH-oxidase was reduced signifi cantly in Ob<br />
in comparison with L (5.63±1.59 and 2.45±0.23 U/mg CL (P=0.02) for L and Ob<br />
subjects, respectively). However, the citrate synthase activity is signifi cantly<br />
higher in obesity in comparison with lean group (35.8±3.4 and 54.5±5.3 U/mg<br />
CL (P=0.02) for L and Ob, respectively).<br />
Analysis of liver mitochondria was performed on a rodent high-fat feeding<br />
model. Five weeks of high–fat feeding in rats (n=4) induces insulin resistance,<br />
decreases specifi c NADH-oxidase activity (1.470±0.53 and 0.997±0.08 U/<br />
mg CL for control (C) and high fat-fed (HF) rats, respectively), signifi cantly<br />
increases citrate synthase activity (19.7±2.1 and 27.4±1.4 U/mg CL (P=0.023)<br />
for C and HF rats, respectively) and slightly decreases liver cardiolipin<br />
content. We hypothesize that excessive dietary fat intake induces activation<br />
of CS (by induction of protein synthesis or by post-translational modifi cation<br />
in liver and skeletal muscle) to utilize excessive acetyl-CoA produced in<br />
beta-oxidation pathway.<br />
These data highlight that mitochondrial TCA cycle and electron transport<br />
chain enzymes respond differently to energy excess. Further investigation is<br />
needed to better understand the respective roles of specifi c mitochondrial<br />
function in obesity and insulin resistance. <strong>ADA</strong>-Funded Research<br />
1684-P<br />
Effect of Ecdysterone on Hepatic AMP Activated Protein Kinase in<br />
Mice Fed with a High-Fat Diet<br />
ZHONG Q. WANG, YONGMEI YU, XIAN H. ZHANG, DAVID RIBNICKY, WILLIAM T.<br />
CEFALU, Baton Rouge, LA, New Brunswick, NJ<br />
Chronic nutrient overload leads to obesity and metabolic disorders,<br />
including insulin resistance and type 2 diabetes. Ecdysterone (Ecdy),<br />
specifi cally20-hydroxyecdysone, is a steroid hormone from plants). Our<br />
previous study showed that Ecdy may have anti-obesity and anti-diabetic<br />
effects, but its molecular mechanisms remain largely unknown. It is well<br />
documented AMP activated protein kinase (AMPK) plays a key role in glucose<br />
metabolism. In order to evaluate the effect of Ecdy on AMPK signaling, we<br />
examined hepatic AMPK pathway proteins in mice fed a low-fat diet (control)<br />
or high-fat diet (HFD) with or without low dose (25 mg/kg body weight, Ecdy<br />
L) or high-dose (50 mg/kg, Ecdy H) of Ecdy for 12 weeks. Body weight, fasting<br />
glucose and insulin concentrations were measured as well. At study end,<br />
no differences in body weight, food intake or energy expenditure were<br />
observed between HFD groups with or without Ecdy L, but the body weight<br />
was signifi cantly lower in Ecdy H group relative to the HFD group (P